Designing synthetic vaccines for HIV

Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies

(2014) Fernando Garces et al.   CELL

Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers

(2014) Emilia Falkowska et al.   IMMUNITY

Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers

(2014) Claudia Blattner et al.   IMMUNITY

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface

(2014) Jinghe Huang et al.   NATURE

Vaccines that stimulate T cell immunity to HIV-1: the next step

(2014) Andrew J McMichael et al.   NATURE IMMUNOLOGY

Host Controls of HIV Neutralizing Antibodies

(2014) B. F. Haynes et al.   SCIENCE

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV

(2014) D. Sok et al.   Science Translational Medicine

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

(2014) Louise Scharf et al.   Cell Reports

Novel approaches in polyepitope T-cell vaccine development against HIV-1

(2013) Larisa I Karpenko et al.   Expert Review of Vaccines

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

(2013) Hua-Xin Liao et al.   IMMUNITY

HIV-1 neutralizing antibodies: understanding nature's pathways

(2013) John R. Mascola et al.   IMMUNOLOGICAL REVIEWS

Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region-Associated Autoreactivity Limits T-Dependent Responses

(2013) L. Verkoczy et al.   JOURNAL OF IMMUNOLOGY

Characterization of Host-Cell Line Specific Glycosylation Profiles of Early Transmitted/Founder HIV-1 gp120 Envelope Proteins

(2013) Eden P. Go et al.   JOURNAL OF PROTEOME RESEARCH

Chemical Synthesis of Highly Congested gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines

(2013) Baptiste Aussedat et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Efficient Convergent Synthesis of Bi-, Tri-, and Tetra-antennary Complex Type N-Glycans and Their HIV-1 Antigenicity

(2013) Sachin S. Shivatare et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

(2013) Hua-Xin Liao et al.   NATURE

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies

(2013) Mohammed N Amin et al.   Nature Chemical Biology

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

(2013) Marie Pancera et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

(2013) Leopold Kong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

(2013) Scott M. Hammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors

(2013) S. M. Alam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9

(2013) Jean-Philippe Julien et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Advance in the Chemical Synthesis of Homogeneous N-Linked Glycopolypeptides by Convergent Aspartylation

(2012) Ping Wang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

(2012) M. S. de Souza et al.   JOURNAL OF IMMUNOLOGY

Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

(2012) S. Munir Alam et al.   JOURNAL OF VIROLOGY

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

(2012) Barton F Haynes et al.   NATURE BIOTECHNOLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses

(2012) D. R. Burton et al.   SCIENCE

New Paradigms for HIV/AIDS Vaccine Development

(2011) Louis J. Picker et al.   Annual Review of Medicine

Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors

(2011) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Characterization of Glycosylation Profiles of HIV-1 Transmitted/Founder Envelopes by Mass Spectrometry

(2011) E. P. Go et al.   JOURNAL OF VIROLOGY

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade

(2011) Camille Bonomelli et al.   PLoS One

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

(2011) R. Pejchal et al.   SCIENCE

Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds

(2010) Rena D. Astronomo et al.   CHEMISTRY & BIOLOGY

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV

(2010) Monica Vaccari et al.   Expert Review of Vaccines

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

(2010) M. Juliana McElrath et al.   IMMUNITY

Yeast-Elicited Cross-Reactive Antibodies to HIV Env Glycans Efficiently Neutralize Virions Expressing Exclusively High-Mannose N-Linked Glycans

(2010) C. Agrawal-Gamse et al.   JOURNAL OF VIROLOGY

Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16

(2010) Katie J. Doores et al.   JOURNAL OF VIROLOGY

Immunology and the elusive AIDS vaccine

(2010) Herbert W. Virgin et al.   NATURE

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

(2010) K. J. Doores et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

(2010) K. J. Doores et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

(2009) David C Montefiori et al.   Current Opinion in HIV and AIDS

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens

A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120

(2008) R. D. Astronomo et al.   JOURNAL OF VIROLOGY

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions

(2008) J. G. Joyce et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN

(2008) S.-K. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA